Skip To Main Content
Zuxiu Wang on Muck Rack

Zuxiu Wang

As seen in: BMC Cancer
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Zuxiu

Contact Zuxiu, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

PD-1/PD-L1 immune checkpoint inhibitors in the treatment of unresectable locally advanced or metastatic triple negative breast cancer: a meta-analysis on their efficacy and safety | BMC Cancer | Full Text

|
By Hanxi Xiao, Xinrong Tang, Yongping Pan, Feng Gao, Zuxiu Wang, Peimeng You, Zhanglei Yang, Xuhuan Li
| BMC Cancer Verified
The latest research found that the expression levels and activity of PD-L1 and tumor-infiltrating lymphocytes (TILs) in TNBC patients were significantly higher than those in other breast cancer subtypes, indicating that TNBC has strong immunogenicity and may be responsive to anti-PD-1 and anti-PD-L1 treatments [21, 22]. Immunotherapy provides a new treatment option for metastatic triple negative breast cancer.
Open in Who Shared Issue with article?
See all 1 articles